EMAC4001

EMAC4001 is an experimental small molecule sunitinib analogue belonging to the isatin-dihydropyrazole chemical class. Developed as a potent antineoplastic agent, it has demonstrated significant activity against human pancreatic cancer cell lines, including MIA PaCa-2 and PANC-1, in both normoxic and hypoxic environments. Preclinical studies indicate that EMAC4001 is substantially more potent than sunitinib in inhibiting cell viability and colony formation, suggesting its potential as a targeted therapy for chemotherapy-resistant pancreatic adenocarcinoma. Its mechanism of action likely involves the multi-targeted inhibition of receptor tyrosine kinases, similar to its parent compound sunitinib, but with enhanced potency and selectivity in pancreatic cancer models.